Biodesix Reports Impressive 45% Revenue Growth in 2024
Friday, Jan 10, 2025 6:06 am ET
1min read Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company, has announced preliminary, unaudited results for the fourth quarter and full-year 2024, showcasing remarkable financial momentum. Total revenue reached an estimated $71.3 million for 2024, marking a 45% increase year-over-year, with Q4 revenue at $20.4 million, up 39%. This significant growth is driven by both core segments, with Lung Diagnostics contributing $64.7 million (up 43%) and Biopharma Services exhibiting exceptional growth of 69%.
Disclaimer: The news articles available on this platform are generated in whole or in part by artificial intelligence and may not have been reviewed or fact checked by human editors. While we make reasonable efforts to ensure the quality and accuracy of the content, we make no representations or warranties, express or implied, as to the truthfulness, reliability, completeness, or timeliness of any information provided. It is your sole responsibility to independently verify any facts, statements, or claims prior to acting upon them. Ainvest Fintech Inc expressly disclaims all liability for any loss, damage, or harm arising from the use of or reliance on AI-generated content, including but not limited to direct, indirect, incidental, or consequential damages.
_442a2dcc1749832873286.jpeg)
_e68fac6d1749831664430.jpeg)
